

Resource Summary Report

Generated by [RRID](#) on Aug 1, 2026

CD3 Monoclonal Antibody (OKT3), Functional Grade, eBioscience

RRID:AB_468855

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 16-0037-85, RRID:AB_468855)

Antibody Information

URL: http://antibodyregistry.org/AB_468855

Proper Citation: (Thermo Fisher Scientific Cat# 16-0037-85, RRID:AB_468855)

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow, Functional

Antibody Name: CD3 Monoclonal Antibody (OKT3), Functional Grade, eBioscience

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_468855

Vendor: Thermo Fisher Scientific

Catalog Number: 16-0037-85

Record Creation Time: 20251216T074118+0000

Record Last Update: 20260225T231603+0000

Ratings and Alerts

No rating or validation information has been found for CD3 Monoclonal Antibody (OKT3), Functional Grade, eBioscience.

No alerts have been found for CD3 Monoclonal Antibody (OKT3), Functional Grade, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lou J, et al. (2025) Step-Wise Assembly of LAT Signaling Clusters Immediately After T Cell Receptor Triggering Contributes to Signal Propagation. International journal of molecular sciences, 26(9).

Zhang W, et al. (2025) Identification of antigen-specific functional CD8+ T cells using an optofluidic system independent of epitope information. iScience, 28(10), 113600.

Cutilli A, et al. (2025) Interferon-gamma induces epithelial reprogramming driving CXCL11-mediated T-cell migration. Journal of leukocyte biology, 117(2).

Lin H, et al. (2025) Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses. Cell reports. Medicine, 6(5), 102117.

Ahn JJ, et al. (2025) Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. Cell reports. Medicine, 6(8), 102257.

Shemorry A, et al. (2025) Engineering ER γ degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases. Cell chemical biology, 32(5), 694.

Perdomo-Celis F, et al. (2025) Impact of rosuvastatin on the memory potential and functionality of CD8+ T cells from people with HIV. EBioMedicine, 114, 105672.

Kirkpatrick C, et al. (2025) Isolation of mitochondrial mutation-specific T cell receptors. Journal of immunology (Baltimore, Md. : 1950).

Thomas-Jardin S, et al. (2025) The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer. Cancer research, 85(14), 2574.

Dijkstra KK, et al. (2025) Subclonal immune evasion in non-small cell lung cancer. Cancer cell.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. *Cell reports*, 43(2), 113712.

Otsuka S, et al. (2024) Calcineurin is an adaptor required for assembly of the TCR signaling complex. *Cell reports*, 43(8), 114568.

Ren Z, et al. (2024) Transient hydroxycholesterol treatment restrains TCR signaling to promote long-term immunity. *Cell chemical biology*, 31(5), 920.

Jansen SA, et al. (2024) Chemotherapy-induced intestinal epithelial damage directly promotes galectin-9-driven modulation of T cell behavior. *iScience*, 27(6), 110072.

Portmann K, et al. (2024) Stimulation-induced cytokine polyfunctionality as a dynamic concept. *eLife*, 12.

Lin CP, et al. (2024) Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness. *Cancer cell*.

Wu L, et al. (2023) CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. *Cell reports. Medicine*, 4(2), 100917.

Afsahi A, et al. (2023) LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling. *Frontiers in immunology*, 14, 1179827.

Kenski JCN, et al. (2023) An adverse tumor-protective effect of IDO1 inhibition. *Cell reports. Medicine*, 4(2), 100941.

Huseni MA, et al. (2023) CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. *Cell reports. Medicine*, 4(1), 100878.